Activity of gemcitabine in non-small-cell lung cancer: Results of the Japan gemcitabine group (A) phase II study

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 3, 1997, Pages 217-222

  Takada, Minoru ^a   Negoro, Shun Ichi ^b,j   Kudo, Shinzo ^c   Furuse, Kiyoyuki ^d   Nishikawa, Hideki ^e   Takada, Yoshiki ^f   Kamei, Tadashi ^g   Niitani, Hisanobu ^h,k   Fukuoka, Masahiro ⁱ  

^a Department of Cardiology   (Japan)

^b Osaka Municipal Momoyama Hospital   (Japan)

^c Osaka Prefecture University   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

^f Hyogo Prefectural Kakogawa Medical Center   (Japan)

^g KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^h NIPPON MEDICAL SCHOOL   (Japan)

ⁱ KINKI UNIVERSITY   (Japan)

^j OSAKA CITY GENERAL HOSPITAL   (Japan)

^k Tokyo Cooperative Oncology Group   (Japan)

more..

Author keywords

Gemcitabine; Japan; NSCLC; Phase II

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031927560     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050731     Document Type: Article

References (22)

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535
2. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821
3. Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, Lippert B, Jarvi E, Resvick R (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34: 1879
4. Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB (1991) Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemeitabine) against human head and neck cancer. Cancer Res 51: 211
5. Carmichael J, Allerheiligen S, Walling J (1996) A phase 1 study of gemcitabine and carboplatin in non-small cell lung cancer (NSCLC). Semin Oncol 23 [suppl 10]: 55
6. Fukuoka M, Noda K, Hasegawa K, (1996) An early phase II study of gemcitabine hydrochloride. Jpn J Cancer Chemother 21: 943
7. Gandhi V, Plunkett W (1990) Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50: 3675
8. Ginsberg RJ, Kris MG, Armstrong JG (1993) Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. JB Lippincott & Co., Philadelphia, p673
9. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48: 4024
10. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417
11. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110
12. Ihde DC (1992) Chemotherapy of lung cancer (review). N Engl J Med 327: 1434
13. Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. Nippon Can Chiryo Gakkai Shi 28: 101
14. Johnson DH (1990) Chemotherapy for unresectable non-small cell lung cancer (Review). Semin Oncol 17: 20
15. Kristjansen PE, Quistorff B, Spang-Thomsen M, Hansen HH (1993) Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. Ann Oncol 4: 157
16. Le Chevalier T, Gottfried M, Gatzemeir M (1993) Confirmatory activity of gemcitabine in non-small-cell lung cancer. Eur J Cancer 29A [suppl 6]: s160
17. Manegold CH, Eberhard W, Wilke H, Gatzemeier D, Chomy F, Chomy P, Khayat D, Blatter J, Seeber S, Drings P (1996) Activity of gemcitabine (GEM) and ifosfamide (IFO) in advanced non-small cell lung cancer (NSCLC): a phase II study. Proc Eur Respir Soc 400s, abstr 2511
18. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Peter JL, Quiox E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP (1993) Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342: 19
19. Steward WP, Dunlop DJ, Cameron C, Talbot DC, Kleisbauer J-P, Thomas P (1995) Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I II study. Anticancer Drugs 6: 33
20. Taguchi T, Furuse K, Fukuoka M et al. (1996) LY188011 phase I study. Jpn J Cancer Chemother 23: 1011
21. Takada M, Yokoyama A, Nakai Y, Negoro S, Fukuoka M, Kurita Y, Niitani H (1994) Late phase II studies of gemcitabine in non-small cell lung cancer (NSCLC). Cooperative study group of gemcitabine for NSCLC in Japan. Proceedings NCI-EORTC 142: 281 (abst.)
22. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. (WHO Offset Publication no. 48) World Health Organization, Geneva